Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials
Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials
复制标题
DOI：
10.1002/jmv.24678
复制
发表时间：
2016-12-01
影响因子：
12.7
通讯作者：
Elfiky, Abdo A.
中科院分区：
文献类型：
--
作者：
Elfiky, Abdo A.
在过去的几个月里，美国爆发了一种新的寨卡病毒(ZIKV)。2016年2月，世界卫生组织(WHO)宣布其为国际关注的突发公共卫生事件(PHEIC)。有60多个国家报告了寨卡病毒感染，自2007年以来，这种疾病一直在传播，但势头不大。许多抗病毒药物在市场上可买到，或在实验室进行临床试验，可能会影响ZIKV感染。在电子对接研究中，对ZIKV聚合酶进行了测试，以测试一些丙型肝炎病毒(丙型肝炎病毒)药物(已批准和正在进行临床试验)。结果表明，几乎所有研究的化合物都对ZIKV聚合酶具有效力，从而抑制了疾病的传播。此外，该研究还提出了两种核苷酸抑制剂(IDX-184和MK0608)，可以作为抗ZIKV感染的药物进行测试。J.Med.维罗尔。88：2044-2051,2016。(C)2016威利期刊公司。
In the last few months, a new Zika virus (ZIKV) outbreak evolved in America. In accordance, World Health Organization (WHO) in February 2016 declared it as Public Health Emergency of International Concern (PHEIC). ZIKV infection was reported in more than 60 countries and the disease was spreading since 2007 but with little momentum. Many antiviral drugs are available in market or in laboratories under clinical trials, could affect ZIKV infection. In silico docking study were performed on the ZIKV polymerase to test some of Hepatitis C Virus (HCV) drugs (approved and in clinical trials). The results show potency of almost all of the studied compounds on ZIKV polymerase and hence inhibiting the propagation of the disease. In addition, the study suggested two nucleotide inhibitors (IDX-184 and MK0608) that may be tested as drugs against ZIKV infection. J. Med. Virol. 88:2044-2051, 2016. (c) 2016 Wiley Periodicals, Inc.